U.S. Obesity Treatment Market is Projected to Grow from USD 6.73 Billion in 2025E to USD 24.35 Billion by 2033 Owing to Rising Obesity Prevalence in the Country
Austin, Feb. 05, 2026 (GLOBE NEWSWIRE) — According to SNS Insider, The Obesity Treatment Market Size is valued at USD 19.52 Billion in 2025E and is projected to reach USD 75.69 Billion by 2033, growing at a CAGR of 18.49% during 2026–2033. Growing prevalence of obesity, metabolic risks, and high uptake of GLP-1–based products will continue to drive growth over the forecast.
At a compound annual growth rate (CAGR) of 17.47%, the U.S. obesity treatment market is expected to increase from USD 6.73 billion in 2025E to USD 24.35 billion by 2033. The rising incidence of obesity, the quick adoption of GLP-1 treatments, the rise in bariatric procedures, and the high degree of clinical integration for cutting-edge weight-management solutions all contribute to growth.
Get a Sample Report of Obesity Treatment Market Growth Strategy @ https://www.snsinsider.com/sample-request/9124
Market Size and Forecast:
- Market Size in 2025: USD 19.52 Billion
- Market Size by 2033: USD 75.69 Billion
- CAGR: 18.49% from 2026 to 2033
- Base Year: 2025
- Forecast Period: 2026–2033
- Historical Data: 2022–2024
Rapid Adoption of High-efficacy GLP-1 Therapies to Propel Market Expansion Globally
Rapid adoption of high-efficacy GLP-1 treatments is a primary force fueling Obesity Treatment Market growth. With the prevalence of obesity increasing and metabolic co-morbidities deepening, demand is moving toward clinically established pharmacological solutions can produce meaningful weight losses which are long lasting. GLP-1 medications provide glycaemic management, weight loss and CV risk reduction, making them mainstay therapy. Their rising indications for usage and increasing clinical adoption are transforming the practice of obesity treatment, raising the bar for long-term therapy.
Major Players Analysis Listed in the Obesity Treatment Market Report
- Novo Nordisk
- Eli Lilly and Company
- Johnson & Johnson
- Pfizer
- AstraZeneca
- Roche Holding AG
- Sanofi
- NovoChem Therapeutics
- MannKind Corporation
- Boehringer Ingelheim
- Eisai Co., Ltd.
- Medtronic plc
- Apollo Endosurgery, Inc.
- GI Dynamics, Inc.
- ReShape Lifesciences Inc.
- Spatz FGIA, Inc.
- Allurion Technologies Inc.
- Sleeve Experts Inc.
- Aspire Bariatrics LLC
Obesity Treatment Market Segmentation Analysis
By Treatment Type
Pharmacotherapy held the largest market share of 48.62% in 2025 as it has been clinically accepted, easy to prescribe and with evidence toward sustained weight reduction. Bariatric Surgery is expected to grow at the fastest CAGR of 19.48% during 2026–2033 due to minimally invasive procedures, enhanced safety, and quicker recovery.
By Drug Class
GLP-1 Receptor Agonists accounted for the highest market share of 53.71% in 2025 as it is the preferred pharmacotherapy with effective weight loss and better cardiometabolic profile. Dual/Triple Agonists (GLP-1/GIP/Glucagon) are projected to expand at the fastest CAGR of 21.34% during the forecast period while having state-of-the-art modalities for multi-pathway weight reduction.
By Surgical Procedure
Sleeve Gastrectomy dominated with a 41.85% share in 2025 on account of its minimally invasive procedure, high success ratio and increasing patient preference. Biliopancreatic Diversion with Duodenal Switch (BPD/DS) is anticipated to record the fastest CAGR of 19.12% through 2026–2033 due to its better long-term weight-loss results and metabolic benefits.
By Medical Device Type
Intragastric Balloons held the largest share of 39.57% in 2025 owing to its easy implantation procedure, reversible nature, and high patient acceptance in non-surgical procedures. Electrical Stimulation Systems are expected to grow at the fastest CAGR of 18.63% during 2026–2033 due to new product launches and increasing demand for non-invasive appetite control.
By End-User
Hospitals & Clinics accounted for the largest share of 45.29% in 2025 with combined package of obesity care, surgeries, pharmacotherapy and specialized follow ups. Homecare Settings are forecasted to register the fastest CAGR of 19.21% during 2026–2033 driven by telemedicine, remote monitoring and orally administered therapies preferred by patients.
Obesity Treatment Market Regional Insights
North America dominated the Obesity Treatment Market, capturing a 41.73% market share in 2025. This leadership is attributable to high prevalence of obesity, high clinical uptake of GLP-1 medicines and excellent bariatric surgical facilities in the area. Strong healthcare infrastructure, attractive reimbursement policies and significant pharmaceutical R&D boost market expansion.
The Asia Pacific Obesity Treatment Market is the fastest-growing globally, estimated to rise at a robust CAGR of 20.85% over 2026–2033. Growing obesity rates, increased access to new weight-loss medications, and increased healthcare spending in China, India, Japan, and Korea are all factors contributing to this increase.
Get Expert-Led Insights for Your Business Strategy — Connect with Analysts Now @ https://www.snsinsider.com/request-analyst/9124
Obesity Treatment Market Recent Developments
- In March 2025, Novo Nordisk announced Phase III success for CagriSema, a semaglutide-cagrilintide combination, demonstrating significant weight loss and metabolic benefits. The launch reinforced Novo’s leadership in obesity treatment and patient access strategies.
- In March 2025, Eli Lilly launched Mounjaro (tirzepatide) in India, expanding its presence. The introduction of the pre-filled KwikPen enhanced patient convenience, adherence, and accessibility, strengthening Lilly’s position in the obesity and diabetes treatment market.
Exclusive Sections of the Report (The USPs)
- TREATMENT UTILIZATION & OUTCOMES METRICS – helps you assess regional treatment penetration, patient adherence levels, intervention success rates, and average weight loss outcomes to gauge real-world effectiveness of obesity therapies.
- DRUG & DEVICE ADOPTION DYNAMICS – helps you identify market leaders and emerging opportunities by tracking market share of pharmacotherapies/devices, adoption of novel treatments, prescription growth trends, and per-patient therapy costs.
- SUPPLY CHAIN & CARE DELIVERY EFFICIENCY – helps you evaluate access barriers by analyzing diagnosis-to-treatment timelines, geographic availability of drugs/devices, stock-out risks, surgical lead times, and specialist provider density.
- REGULATORY COMPLIANCE & SAFETY INDICATORS – helps you understand regulatory pressure and patient safety risks through guideline adherence rates, adverse event frequency, recall trends, and adoption of standardized monitoring protocols.
- REIMBURSEMENT & MARKET ACCESS INSIGHTS – helps you determine commercial viability by assessing insurance coverage levels, reimbursement penetration for therapies/devices, and their impact on patient enrollment and treatment uptake.
Obesity Treatment Market Report Scope
| Report Attributes | Details |
| Market Size in 2025E | USD 19.52 Billion |
| Market Size by 2033 | USD 75.69 Billion |
| CAGR | CAGR of 18.49% From 2026 to 2033 |
| Base Year | 2025E |
| Forecast Period | 2026-2033 |
| Historical Data | 2022-2024 |
| Key Segments | • By Treatment Type (Pharmacotherapy, Bariatric Surgery, Lifestyle Intervention Programs, Dietary Supplements, Medical Devices, Others) • By Drug Class (GLP-1 Receptor Agonists, Dual/Triple Agonists, Combination Drugs, Serotonin Agonists, Lipase Inhibitors, Others) • By Surgical Procedure (Gastric Bypass, Sleeve Gastrectomy, Adjustable Gastric Banding, Biliopancreatic Diversion with Duodenal Switch, Others) • By Medical Device Type (Intragastric Balloons, Electrical Stimulation Systems, Gastric Emptying Systems, Appetite Suppression Devices, Others) • By End-User (Hospitals & Clinics, Bariatric Surgery Centers, Weight Loss Centers, Homecare Settings, Others) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Purchase Comprehensive Obesity Treatment Market Report – Single User PDF @ https://www.snsinsider.com/checkout/9124
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Data Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.
